Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEWLAN: Insulin Glargine in Uncontrolled T2DM
NCT02606357Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2015
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Nov 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02606357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606357.